Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Stephano Del PratoJuan Pablo FriasLawrence BlondeVanita R ArodaNiam ShehadehAramesh SaremiTerry DexElisabeth NiemoellerElisabeth SouhamiMinzhi LiuJulio RosenstockPublished in: Diabetes, obesity & metabolism (2020)
The results of this study suggest that iGlarLixi is an effective treatment option, irrespective of C-peptide levels or duration of diabetes, in adults with insufficiently controlled T2D receiving GLP-1 RAs.